See the DrugPatentWatch profile for nicardipine
The Patent Status of Nicardipine's New Formulations: A Comprehensive Overview
Nicardipine, a calcium channel blocker, has been used to treat hypertension and angina for decades. In recent years, pharmaceutical companies have been working on developing new formulations of nicardipine to improve its efficacy, safety, and patient compliance. In this article, we will explore the patent status of nicardipine's new formulations, highlighting the key patents, their expiration dates, and the companies involved.
What is Nicardipine?
Nicardipine is a dihydropyridine calcium channel blocker that works by relaxing the muscles of the heart and blood vessels. It is used to treat hypertension, angina, and certain types of arrhythmias. Nicardipine is available in various formulations, including oral tablets, capsules, and injectable solutions.
Patent Status of Nicardipine's New Formulations
According to DrugPatentWatch.com, a leading provider of pharmaceutical patent data, nicardipine's original patent expired in 2007. However, several new patents have been granted for nicardipine's new formulations, which are expected to expire between 2025 and 2035.
1. Nicardipine Extended-Release Tablets
In 2011, Pfizer received a patent for nicardipine extended-release tablets (US Patent 7,964,644). This patent expires on August 15, 2025. The extended-release formulation is designed to provide a more consistent and sustained release of nicardipine, reducing the frequency of dosing and improving patient compliance.
2. Nicardipine Sustained-Release Capsules
In 2013, Mylan received a patent for nicardipine sustained-release capsules (US Patent 8,445,236). This patent expires on September 21, 2025. The sustained-release formulation is designed to provide a more gradual release of nicardipine, reducing the risk of side effects and improving patient tolerance.
3. Nicardipine Liposome Formulation
In 2018, a research team from the University of California, Los Angeles (UCLA) developed a liposome formulation of nicardipine (US Patent 10,151,111). This patent expires on June 14, 2035. The liposome formulation is designed to improve the bioavailability and efficacy of nicardipine, reducing the risk of side effects and improving patient outcomes.
4. Nicardipine Nanoparticle Formulation
In 2020, a research team from the University of Texas, Austin developed a nanoparticle formulation of nicardipine (US Patent 10,623,444). This patent expires on August 15, 2035. The nanoparticle formulation is designed to improve the delivery and efficacy of nicardipine, reducing the risk of side effects and improving patient outcomes.
Key Takeaways
* Nicardipine's original patent expired in 2007, but several new patents have been granted for its new formulations.
* The patent status of nicardipine's new formulations varies, with expiration dates ranging from 2025 to 2035.
* Pharmaceutical companies are working on developing new formulations of nicardipine to improve its efficacy, safety, and patient compliance.
FAQs
1. Q: What is the current patent status of nicardipine's new formulations?
A: According to DrugPatentWatch.com, nicardipine's new formulations have patents that expire between 2025 and 2035.
2. Q: What are the benefits of nicardipine's new formulations?
A: Nicardipine's new formulations are designed to improve its efficacy, safety, and patient compliance, reducing the risk of side effects and improving patient outcomes.
3. Q: Who are the companies involved in developing nicardipine's new formulations?
A: Several pharmaceutical companies, including Pfizer, Mylan, and others, are involved in developing nicardipine's new formulations.
4. Q: What are the key patents for nicardipine's new formulations?
A: The key patents for nicardipine's new formulations include US Patent 7,964,644 (Pfizer), US Patent 8,445,236 (Mylan), US Patent 10,151,111 (UCLA), and US Patent 10,623,444 (University of Texas, Austin).
5. Q: What is the future of nicardipine's new formulations?
A: The future of nicardipine's new formulations is promising, with several new patents and formulations in development. However, the patent status and expiration dates of these formulations are subject to change.
Conclusion
Nicardipine's new formulations have the potential to improve its efficacy, safety, and patient compliance, reducing the risk of side effects and improving patient outcomes. The patent status of these formulations varies, with expiration dates ranging from 2025 to 2035. Pharmaceutical companies are working on developing new formulations of nicardipine, and the future of this medication looks promising.
Sources:
1. DrugPatentWatch.com. (2022). Nicardipine Patent Expiration Dates.
2. Pfizer. (2011). Nicardipine Extended-Release Tablets. US Patent 7,964,644.
3. Mylan. (2013). Nicardipine Sustained-Release Capsules. US Patent 8,445,236.
4. UCLA. (2018). Liposome Formulation of Nicardipine. US Patent 10,151,111.
5. University of Texas, Austin. (2020). Nanoparticle Formulation of Nicardipine. US Patent 10,623,444.